Piper Jaffray downgraded Alcobra Pharma (NASDAQ:ADHD) from Overweight to Neutral in a report released today.
- Updated: September 30, 2016
Piper Jaffray has downgraded Alcobra Pharma (NASDAQ:ADHD) from Overweight to Neutral in a report released on Friday September 30, 2016.
Just yesterday Alcobra Pharma (NASDAQ:ADHD) traded -1.60% lower at $2.51. The company’s 50-day moving average is $4.76 and its 200-day moving average is $4.52. The last stock close price is down -45.36% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 730,128 shares of the stock traded hands, up from an average trading volume of 244,255
See Chart Below
Alcobra Pharma has a 52 week low of $1.95 and a 52 week high of $8.78 The company’s market cap is currently $0.
In addition to Piper Jaffray reporting its stock price target, a total of 7 brokers have issued a report on ADHD. The one year target is $12.71 with three equity analysts rating the company a strong buy, three equity analysts rating the company a buy, zero brokerages rating the company a hold, zero brokerages rating the company a underperform, and lastly zero analysts rating the company a sell.
More About Alcobra Pharma (NASDAQ:ADHD)
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse. MG01CI product has completed phase two studies.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.